	US 12,228,580 B2
	Methods of assigning a COVID pathological type based on a cytokine/chemokine panel
Bruce K. Patterson, Menlo Park, CA (US); Edgar B. Francisco, San Carlos, CA (US); Amruta Pise, San Carlos, CA (US); and Emily Long, San Carlos, CA (US)
Assigned to IncellDx, Inc., Hayward, CA (US)
Filed by IncellDx, Inc., San Carlos, CA (US)
Filed on Jun. 16, 2022, as Appl. No. 17/842,293.
Application 17/842,293 is a continuation of application No. 17/351,055, filed on Jun. 17, 2021, granted, now 11,402,391.
Claims priority of provisional application 63/166,704, filed on Mar. 26, 2021.
Claims priority of provisional application 63/128,471, filed on Dec. 21, 2020.
Prior Publication US 2022/0317134 A1, Oct. 6, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 31/4178 (2006.01); A61K 31/46 (2006.01); A61K 31/506 (2006.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [A61K 31/4178 (2013.01); A61K 31/46 (2013.01); A61K 31/506 (2013.01); A61K 38/195 (2013.01); A61K 45/06 (2013.01); C07K 16/2866 (2013.01); C07K 2317/24 (2013.01); G01N 2333/521 (2013.01); G01N 2800/52 (2013.01)]

13 Claims

1. A method comprising:

i) receiving a test sample obtained from a subject having COVID;

ii) contacting the test sample with binding members for a quantitative, multiplex cytokine/chemokine panel;

iii) quantitatively measuring the multiplex cytokine/chemokine panel in the test sample, wherein the cytokine/chemokine panel comprises at least:

a) IFN-γ, IL-2 and CCL4 (MIP-1β); or

b) IL-10, IL-6, IL-13, IL-2 and IL-8.